Cargando…
Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics
BACKGROUND: Tumor-specific mutated proteins can create immunogenic non-self, mutation-containing ‘neoepitopes’ that are attractive targets for adoptive T-cell therapies. To avoid the complexity of defining patient-specific, private neoepitopes, there has been major interest in targeting common share...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537849/ https://www.ncbi.nlm.nih.gov/pubmed/37758652 http://dx.doi.org/10.1136/jitc-2023-007097 |
_version_ | 1785113190420447232 |
---|---|
author | Ade, Catherine M Sporn, Matthew J Das, Sudipto Yu, Zhiya Hanada, Ken-ichi Qi, Yue A Maity, Tapan Zhang, Xu Guha, Udayan Andresson, Thorkell Yang, James C |
author_facet | Ade, Catherine M Sporn, Matthew J Das, Sudipto Yu, Zhiya Hanada, Ken-ichi Qi, Yue A Maity, Tapan Zhang, Xu Guha, Udayan Andresson, Thorkell Yang, James C |
author_sort | Ade, Catherine M |
collection | PubMed |
description | BACKGROUND: Tumor-specific mutated proteins can create immunogenic non-self, mutation-containing ‘neoepitopes’ that are attractive targets for adoptive T-cell therapies. To avoid the complexity of defining patient-specific, private neoepitopes, there has been major interest in targeting common shared mutations in driver genes using off-the-shelf T-cell receptors (TCRs) engineered into autologous lymphocytes. However, identifying the precise naturally processed neoepitopes to pursue is a complex and challenging process. One method to definitively demonstrate whether an epitope is presented at the cell surface is to elute peptides bound to a specific major histocompatibility complex (MHC) allele and analyze them by mass spectrometry (MS). These MS data can then be prospectively applied to isolate TCRs specific to the neoepitope. METHODS: We created mono-allelic cell lines expressing one class I HLA allele and one common mutated oncogene in order to eliminate HLA deconvolution requirements and increase the signal of recovered peptides. MHC-bound peptides on the surface of these cell lines were immunoprecipitated, purified, and analyzed using liquid chromatography-tandem mass spectrometry, producing a list of mutation-containing minimal epitopes. To validate the immunogenicity of these neoepitopes, HLA-transgenic mice were vaccinated using the minimal peptides identified by MS in order to generate neoepitope-reactive TCRs. Specificity of these candidate TCRs was confirmed by peptide titration and recognition of transduced targets. RESULTS: We identified precise neoepitopes derived from mutated isoforms of KRAS, EGFR, BRAF, and PIK3CA presented by HLA-A*03:01 and/or HLA-A*11:01 across multiple biological replicates. From our MS data, we were able to successfully isolate murine TCRs that specifically recognize four HLA-A*11:01 restricted neoepitopes (KRAS G13D, PIK3CA E545K, EGFR L858R and BRAF V600E) and three HLA-A*03:01 restricted neoepitopes (KRAS G12V, EGFR L858R and BRAF V600E). CONCLUSIONS: Our data show that an MS approach can be used to demonstrate which shared oncogene-derived neoepitopes are processed and presented by common HLA alleles, and those MS data can rapidly be used to develop TCRs against these common tumor-specific antigens. Although further characterization of these neoepitope-specific murine TCRs is required, ultimately, they have the potential to be used clinically for adoptive cell therapy. |
format | Online Article Text |
id | pubmed-10537849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-105378492023-09-29 Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics Ade, Catherine M Sporn, Matthew J Das, Sudipto Yu, Zhiya Hanada, Ken-ichi Qi, Yue A Maity, Tapan Zhang, Xu Guha, Udayan Andresson, Thorkell Yang, James C J Immunother Cancer Basic Tumor Immunology BACKGROUND: Tumor-specific mutated proteins can create immunogenic non-self, mutation-containing ‘neoepitopes’ that are attractive targets for adoptive T-cell therapies. To avoid the complexity of defining patient-specific, private neoepitopes, there has been major interest in targeting common shared mutations in driver genes using off-the-shelf T-cell receptors (TCRs) engineered into autologous lymphocytes. However, identifying the precise naturally processed neoepitopes to pursue is a complex and challenging process. One method to definitively demonstrate whether an epitope is presented at the cell surface is to elute peptides bound to a specific major histocompatibility complex (MHC) allele and analyze them by mass spectrometry (MS). These MS data can then be prospectively applied to isolate TCRs specific to the neoepitope. METHODS: We created mono-allelic cell lines expressing one class I HLA allele and one common mutated oncogene in order to eliminate HLA deconvolution requirements and increase the signal of recovered peptides. MHC-bound peptides on the surface of these cell lines were immunoprecipitated, purified, and analyzed using liquid chromatography-tandem mass spectrometry, producing a list of mutation-containing minimal epitopes. To validate the immunogenicity of these neoepitopes, HLA-transgenic mice were vaccinated using the minimal peptides identified by MS in order to generate neoepitope-reactive TCRs. Specificity of these candidate TCRs was confirmed by peptide titration and recognition of transduced targets. RESULTS: We identified precise neoepitopes derived from mutated isoforms of KRAS, EGFR, BRAF, and PIK3CA presented by HLA-A*03:01 and/or HLA-A*11:01 across multiple biological replicates. From our MS data, we were able to successfully isolate murine TCRs that specifically recognize four HLA-A*11:01 restricted neoepitopes (KRAS G13D, PIK3CA E545K, EGFR L858R and BRAF V600E) and three HLA-A*03:01 restricted neoepitopes (KRAS G12V, EGFR L858R and BRAF V600E). CONCLUSIONS: Our data show that an MS approach can be used to demonstrate which shared oncogene-derived neoepitopes are processed and presented by common HLA alleles, and those MS data can rapidly be used to develop TCRs against these common tumor-specific antigens. Although further characterization of these neoepitope-specific murine TCRs is required, ultimately, they have the potential to be used clinically for adoptive cell therapy. BMJ Publishing Group 2023-09-27 /pmc/articles/PMC10537849/ /pubmed/37758652 http://dx.doi.org/10.1136/jitc-2023-007097 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Basic Tumor Immunology Ade, Catherine M Sporn, Matthew J Das, Sudipto Yu, Zhiya Hanada, Ken-ichi Qi, Yue A Maity, Tapan Zhang, Xu Guha, Udayan Andresson, Thorkell Yang, James C Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics |
title | Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics |
title_full | Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics |
title_fullStr | Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics |
title_full_unstemmed | Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics |
title_short | Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics |
title_sort | identification of neoepitope reactive t-cell receptors guided by hla-a*03:01 and hla-a*11:01 immunopeptidomics |
topic | Basic Tumor Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537849/ https://www.ncbi.nlm.nih.gov/pubmed/37758652 http://dx.doi.org/10.1136/jitc-2023-007097 |
work_keys_str_mv | AT adecatherinem identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics AT spornmatthewj identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics AT dassudipto identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics AT yuzhiya identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics AT hanadakenichi identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics AT qiyuea identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics AT maitytapan identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics AT zhangxu identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics AT guhaudayan identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics AT andressonthorkell identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics AT yangjamesc identificationofneoepitopereactivetcellreceptorsguidedbyhlaa0301andhlaa1101immunopeptidomics |